1. Home
  2. SNDX vs PWP Comparison

SNDX vs PWP Comparison

Compare SNDX & PWP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNDX
  • PWP
  • Stock Information
  • Founded
  • SNDX 2005
  • PWP 2006
  • Country
  • SNDX United States
  • PWP United States
  • Employees
  • SNDX N/A
  • PWP N/A
  • Industry
  • SNDX Biotechnology: Pharmaceutical Preparations
  • PWP Finance: Consumer Services
  • Sector
  • SNDX Health Care
  • PWP Finance
  • Exchange
  • SNDX Nasdaq
  • PWP Nasdaq
  • Market Cap
  • SNDX 1.4B
  • PWP 1.5B
  • IPO Year
  • SNDX 2016
  • PWP N/A
  • Fundamental
  • Price
  • SNDX $13.63
  • PWP $25.15
  • Analyst Decision
  • SNDX Strong Buy
  • PWP Hold
  • Analyst Count
  • SNDX 11
  • PWP 3
  • Target Price
  • SNDX $37.64
  • PWP $18.83
  • AVG Volume (30 Days)
  • SNDX 1.9M
  • PWP 471.0K
  • Earning Date
  • SNDX 11-05-2024
  • PWP 02-06-2025
  • Dividend Yield
  • SNDX N/A
  • PWP 1.13%
  • EPS Growth
  • SNDX N/A
  • PWP N/A
  • EPS
  • SNDX N/A
  • PWP N/A
  • Revenue
  • SNDX $16,000,000.00
  • PWP $864,769,000.00
  • Revenue This Year
  • SNDX N/A
  • PWP $35.92
  • Revenue Next Year
  • SNDX N/A
  • PWP $13.81
  • P/E Ratio
  • SNDX N/A
  • PWP N/A
  • Revenue Growth
  • SNDX N/A
  • PWP 39.74
  • 52 Week Low
  • SNDX $13.26
  • PWP $10.73
  • 52 Week High
  • SNDX $25.34
  • PWP $26.62
  • Technical
  • Relative Strength Index (RSI)
  • SNDX 30.64
  • PWP 51.50
  • Support Level
  • SNDX $13.36
  • PWP $23.86
  • Resistance Level
  • SNDX $14.18
  • PWP $25.53
  • Average True Range (ATR)
  • SNDX 0.81
  • PWP 0.75
  • MACD
  • SNDX -0.18
  • PWP -0.25
  • Stochastic Oscillator
  • SNDX 11.32
  • PWP 42.32

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.

About PWP Perella Weinberg Partners

Perella Weinberg Partners is an independent advisory firm that provides strategic and financial advice to a wide range of clients. The Company's activities as an investment banking advisory firm constitute a single business segment that provides a range of advisory services, including advice related to strategic and financial decisions, mergers and acquisitions execution, shareholder and defense advisory, financing and capital solutions advice with resources focused on restructuring and liability management, capital markets advisory, private capital placement, as well as specialized underwriting and research services for the energy and related industries.

Share on Social Networks: